Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening
Shield is the first blood test approved by the U.S. Food and Drug Administration (FDA) as a primary screening option for CRC. The second leading cause of cancer-related deaths in the U.S., CRC has a 91 percent five-year survival rate if caught in early stages. Yet one out of three eligible adults in the U.S. (over 50 million people) do not complete the recommended screening in part because they find the available options—colonoscopy and stool tests—unpleasant or inconvenient. With Shield, individuals can be screened with a simple blood draw during a routine office visit, helping to detect more cancers early, when they are more treatable.
"With a simple blood draw, Shield provides a more convenient and pleasant screening option for the millions of people who delay their recommended screening for colorectal cancer," said AmirAli Talasaz, Guardant Health co-founder and co-CEO. "This latest honor for Shield recognizes the groundbreaking innovation created by our team at Guardant Health and the world-changing potential of the Shield blood test. By overcoming barriers with current screening methods, we can help increase the overall screening rate, find more cancers at an early stage, and give people more time free from cancer."
A panel of Fast Company editors and reporters selected the winners from a pool of more than 1,500 entries and judged applications based on their impact, sustainability, design, creativity, scalability, and ability to improve society. This year's awards are featured on fastcompany.com.
"The World Changing Ideas Awards have always been about showcasing the art of the possible," says Fast Company editor-in-chief Brendan Vaughan. "We're proud to recognize the organizations and leaders that are making meaningful progress on the biggest issues of our time."
The Shield blood test was also named to TIME's list of the best inventions of 2024 and selected as a Grand Award Winner in Popular Science's Best of What's New 2024 (Health category). Shield is also the first blood test that is FDA approved for primary screening to be included in The National Comprehensive Cancer Network (NCCN) colorectal cancer (CRC) screening guidelines.
Shield is FDA approved for primary non-invasive screening for colorectal cancer in average-risk individuals age 45 and older and can be ordered by any prescribing healthcare provider. For more information, visit www.ShieldCancerScreen.com.
About Shield
Shield is a non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the disease, age 45 or older, and is not intended for individuals at high risk for colorectal cancer. The Shield test can be considered in a manner similar to guideline-recommended non-invasive CRC screening options and can be completed during any healthcare visit. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Guardant Health Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250610836481/en/
Contacts
Investor Contact: Zarak Khurshidinvestors@guardanthealth.com
Media Contact: Michael Weistpress@guardanthealth.com +1 317-371-0035
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Abacus Global Management Announces Successful Completion of Exchange Offer and Consent Solicitation
ORLANDO, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. ('Abacus' or the 'Company') (NASDAQ: ABL), a leader in the alternative asset management space, today announced the completion of its previously announced exchange offer (the 'Offer') and consent solicitation (the 'Consent Solicitation') relating to its (i) outstanding public warrants (the 'public warrants') and (ii) outstanding private placement warrants (the 'private placement warrants' and, together with the public warrants, the 'warrants') to purchase shares of common stock, par value $0.0001 per share, of the Company ('common stock'). The Company's common stock and public warrants are listed on the Nasdaq Capital Market (the 'Nasdaq') under the symbols 'ABL' and 'ABLLW,' respectively. The Company issued 4,183,160 shares of common stock in exchange for the warrants tendered in the Offer. On July 30, 2025, the Company and Continental Stock Transfer & Trust Company entered into the related amendment to the warrant agreement governing the warrants (the 'Warrant Amendment'). Pursuant to the Warrant Amendment, the Company has exercised its right to exchange each warrant that is outstanding upon the closing of the Offer for 0.207 shares of common stock per warrant, which is a ratio 10% less than the exchange ratio applicable to the Offer (the 'Post-Offer Exchange'). The Company has fixed the date for the Post-Offer Exchange as August 14, 2025. As a result of the completion of the Offer and the Post-Offer Exchange, no warrants will remain outstanding. Accordingly, the public warrants are expected to be suspended from trading on the Nasdaq as of the close of business on August 14, 2025, and will be delisted. The shares of common stock will continue to be listed and trade on the Nasdaq under the symbol 'ABL.' Following completion of the Offer, there are approximately 102,050,981 shares of common stock outstanding (an increase of approximately 4% from prior to the closing of the Offer), and following completion of the Post-Offer Exchange there will be approximately 102,555,154 shares of common stock outstanding (an increase of approximately 5% from prior to the closing of the Offer and the Post-Offer Exchange). The Company engaged SG Americas Securities, LLC as the dealer manager for the Offer and Consent Solicitation, D.F. King & Co., Inc. as the information agent for the Offer and Consent Solicitation, and Continental Stock Transfer & Trust Company served as the exchange agent for the Offer and Consent Solicitation. About Abacus Abacus Global Management (NASDAQ: ABL) is a leading financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. With a focus on longevity-based assets and personalized financial planning, Abacus leverages proprietary data analytics and decades of industry expertise to deliver innovative solutions that optimize financial outcomes for individuals and institutions worldwide. Contacts: Investor RelationsRobert F. Phillips – SVP Investor Relations and Corporate Affairs rob@ 290-1198 David Jackson – Managing Director of Investor Relations david@ 299-0716 Abacus Global Management Public Relationspress@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Can Roku's Q2 Ad Gains and Cost Cuts Rekindle Investor Faith?
Roku Inc. (NASDAQ:ROKU) will report second-quarter earnings after the close on Thursday, July 31. Analysts expect a loss of $0.15 per share on $1.071 billion in revenue, reflecting modest top-line growth but a 40% improve on the bottom-line, as the company works to reaccelerate its ad platform and operational scalability. Shares are up 21% year-to-date but still down more than 80% from its all-time high of $490.76 set on July 27, 2021. Investors will watch closely for signs that platform revenue is recovering after a sluggish 2023. Key metrics will include average revenue per user (ARPU), total streaming hours, and account growth. Roku's high-margin platform business is expected to offset hardware losses, but bulls want to see evidence of improving monetization and a clearer path to EBITDA breakeven. Any commentary on licensing deals for the Roku OS or international expansion could also be well received. Cost discipline will remain in focus. After multiple rounds of layoffs and ad-tech consolidation, Roku has narrowed its losses and guided toward positive adjusted EBITDA by year-end. Investors will also be looking for any updates on AI integration across its ad targeting stack, as peers invest heavily in data-driven automation. While the stock has rebounded, sentiment remains fragile, and execution on margins may matter more than headline growth this quarter. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
8 minutes ago
- Yahoo
T. Rowe Q2 Earnings Preview: Can Market Gains Finally Stop the Bleeding?
T. Rowe Price Group Inc. (NASDAQ:TROW) will report second-quarter earnings before the market opens on Friday, August 1. Analysts expect EPS of $2.15 on $1.728 billion in revenue, representing flat growth as market-driven AUM recovery offsets continued pressure on flows. The stock has lagged year-to-date, weighed down by tepid organic growth, cost control efforts, and ongoing concerns over the competitiveness of active strategies. Key metrics will include total AUM, organic net flows, and average fee rate trends. While the S&P 500 and other major benchmarks posted strong gains in Q2, investor sentiment remains cautious over whether T. Rowe can convert market beta into net inflows. T. Rowe reported net outflows of $8.6 billion in Q1 2025, marking its sixteenth consecutive quarter of redemptions, meaning even a modest inflow this quarter would represent a meaningful break in trend and could help shift sentiment. Expense discipline will also be in focus as management seeks to protect margins without compromising strategic investments, particularly in retirement solutions and model portfolios. With shares still more than 50% below their all-time high, bulls are watching for signs that heightened volatility, recent market strength, and renewed interest in active management can lift both earnings and sentiment. But without clearer evidence of flow stabilization or traction in new products, the upside may remain capped. This article first appeared on GuruFocus.
